Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.
about
Development of an in vivo target-engagement biomarker for TRPA1 antagonists in humans.Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.
P2860
Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Development of anti-migraine t ...... duced dermal blood flow model.
@ast
Development of anti-migraine t ...... duced dermal blood flow model.
@en
type
label
Development of anti-migraine t ...... duced dermal blood flow model.
@ast
Development of anti-migraine t ...... duced dermal blood flow model.
@en
prefLabel
Development of anti-migraine t ...... duced dermal blood flow model.
@ast
Development of anti-migraine t ...... duced dermal blood flow model.
@en
P2860
P356
P1476
Development of anti-migraine t ...... duced dermal blood flow model.
@en
P2093
Jan de Hoon
Steve Vermeersch
P2860
P304
P356
10.1111/BCP.12704
P407
P577
2015-06-26T00:00:00Z